Dynorphin A
Dynorphin A is a 17-amino acid endogenous opioid peptide derived from prodynorphin that acts primarily as a kappa-opioid receptor (KOR) agonist, with research applications in pain modulation, stress responses, addiction neurobiology, and mood disorders.
Dynorphin A is a 17-amino acid endogenous opioid peptide produced from the prodynorphin (PDYN) precursor protein. First identified by Goldstein et al. in 1979, dynorphin A is the primary endogenous agonist of the kappa-opioid receptor (KOR) and plays central roles in pain modulation, stress responses, reward circuitry, and mood regulation.
Overview
Dynorphin A belongs to the endogenous opioid peptide family alongside enkephalins and endorphins, but is distinguished by its preferential activation of the kappa-opioid receptor rather than mu- or delta-opioid receptors. The dynorphin/KOR system functions as an endogenous anti-reward and stress-response mechanism: stressors, chronic pain, and drug exposure upregulate dynorphin release in the nucleus accumbens and prefrontal cortex, producing dysphoria and aversion that counterbalance reward-driven behaviors. Elevated dynorphin/KOR signaling is implicated in the negative emotional states of drug withdrawal, chronic stress-induced depression, and the transition from acute to chronic pain. At high concentrations, dynorphin A also interacts with NMDA receptors through non-opioid mechanisms, contributing to excitotoxicity and neurodegeneration under pathological conditions.
Mechanism of Action
Dynorphin A exerts its primary effects through high-affinity binding to the kappa-opioid receptor (KOR), a Gi/o-coupled GPCR expressed throughout the central and peripheral nervous systems. KOR activation inhibits adenylyl cyclase, reduces cAMP levels, activates inwardly rectifying potassium channels (GIRKs), and inhibits voltage-gated calcium channels — collectively suppressing neuronal excitability and neurotransmitter release (Bruchas et al., 2010).
KOR activation by dynorphin A produces effects that are functionally opposite to mu-opioid receptor stimulation: dysphoria rather than euphoria, aversion rather than reward, and stress-like rather than anxiolytic states. This occurs through KOR-mediated inhibition of dopamine release in the nucleus accumbens and activation of p38 MAPK and JNK stress signaling cascades (Chavkin, 2013).
At supraphysiological concentrations, dynorphin A interacts with NMDA glutamate receptors through a non-opioid mechanism involving the peptide's C-terminal basic residues. This NMDA activity can produce excitotoxic neuronal damage and has been implicated in spinal cord injury pathology and neurodegenerative cascades independent of opioid receptor signaling.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Pain Modulation
Dynorphin A plays a complex dual role in pain processing. At physiological concentrations, KOR activation produces analgesia, particularly in visceral and inflammatory pain models. However, chronic pain states upregulate prodynorphin expression in the spinal dorsal horn, and the resulting elevated dynorphin levels contribute to central sensitization and chronic pain maintenance through both KOR-dependent and NMDA-dependent mechanisms. This paradox — endogenous analgesic peptide contributing to chronic pain — has made the dynorphin/KOR system a target for novel analgesic development.
Stress, Depression, and Addiction
The dynorphin/KOR system is the brain's primary stress-activated anti-reward pathway. Chronic stress, drug withdrawal, and aversive experiences upregulate dynorphin release in limbic circuits. Bruchas et al. (2010) demonstrated that stress-induced dynorphin release activates KOR on serotonergic neurons in the dorsal raphe nucleus, producing depressive-like behaviors through p38 MAPK signaling (PMID: 20336665). Chavkin (2013) provided a comprehensive framework showing that dynorphin/KOR signaling mediates the dysphoria of drug withdrawal and drives escalation of drug intake in addiction models (PMID: 23295395).
PDYN Polymorphisms and Addiction Vulnerability
Genetic variation in the prodynorphin gene (PDYN) influences addiction susceptibility. Polymorphisms in the PDYN promoter region affect dynorphin expression levels, with certain variants associated with increased vulnerability to alcohol dependence, cocaine addiction, and opioid use disorder. These findings support the dynorphin/KOR system as a genetically modifiable risk factor for substance use disorders and a potential target for pharmacogenomic-guided treatment.
Neuroprotection and Neurodegeneration
Dynorphin A exhibits context-dependent effects on neuronal survival. At physiological KOR-activating concentrations, the peptide can be neuroprotective through preconditioning-like mechanisms and reduced excitatory transmission. However, at pathologically elevated concentrations — as seen in spinal cord injury, stroke, and epilepsy — dynorphin A's non-opioid NMDA receptor activity produces excitotoxic neuronal death. This dual nature makes dynorphin A both a potential neuroprotectant and a neurotoxin depending on concentration and context.
Safety Profile
Dynorphin A is an endogenous peptide with well-characterized physiological roles. Exogenous KOR agonism produces dose-dependent dysphoria, sedation, diuresis, and at higher doses, psychotomimetic effects (hallucinations, dissociation). These effects are mediated by KOR activation and represent the primary limitation of therapeutic applications. The plant-derived KOR agonist salvinorin A (from Salvia divinorum) produces similar effects and serves as a pharmacological comparator, demonstrating that potent KOR agonism reliably produces aversive subjective experiences. Dynorphin A's non-opioid NMDA activity at high concentrations raises additional neurotoxicity concerns. Research applications use carefully controlled doses to dissect KOR-dependent from NMDA-dependent effects.
Pharmacokinetic Profile
- Half-life
- Minutes (rapid enzymatic degradation in vivo)
Quick Start
- Route
- Intracerebroventricular, intrathecal, intraperitoneal (research only)
Molecular Structure
- Formula
- C99H155N29O23
- Weight
- 2147.5 Da
- CAS
- 80448-90-4
Research Protocols
intrathecal Injection
Clinical Research Protocols Pain Studies Intrathecal dynorphin A administration in rodent models typically uses 1-10 nmol doses to study spinal pain modulation. Higher doses (10-30 nmol intrathecal) produce paradoxical hyperalgesia through NMDA receptor activation, illustrating the peptide's dual m
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| 1-10 nmol | 10-20 mg, 10 mg | Per protocol | —(Route: Intrathecal) |
intracerebroventricular Injection
Exogenously administered dynorphin A has limited blood-brain barrier penetration due to its charge and size, necessitating central (intrathecal, intracerebroventricular) administration for CNS studies.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Rodents | 10-20 mg | Per protocol | — |
intraperitoneal Injection
Administered via intraperitoneal.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Rodents | 10-20 mg | Per protocol | — |
Interactions
Peptide Interactions
KOR antagonists (nor-binaltorphimine, JDTic, aticaprant) are the primary pharmacological tools used alongside dynorphin A research. By blocking KOR, these compounds reverse dynorphin-mediated dysphoria and are under clinical investigation for treatment-resistant depression and substance use disor...
Quality Indicators
What to look for
- Phase 3 clinical trial data available
Frequently Asked Questions
References (6)
- [9]Martinez et al — Dynorphin/KOR system in chronic pain: from mechanism to therapeutic target Pain (2023)
- [10]Tejeda & Bhavold — Prefrontal cortical kappa opioid receptors in psychiatric disorders Biol Psychiatry (2022)
- [1]Goldstein et al *PNAS* PNAS (1979)
- [2]Bruchas et al *J Neurosci* J Neurosci (2010)
- [3]Chavkin *Neuropsychopharmacology* Neuropsychopharmacology (2013)
- [4]Knoll & Bhavold *Handb Exp Pharmacol* Handb Exp Pharmacol (2016)
DSIP (Delta Sleep-Inducing Peptide)
DSIP is a naturally occurring nonapeptide neuromodulator that promotes delta-wave sleep patterns and modulates stress responses. It interacts with multiple neurotransmitter systems including opioid, serotonergic, and GABAergic pathways.
Ecnoglutide (XW003)
Ecnoglutide (XW003) is a long-acting Fc-fusion GLP-1 receptor agonist developed by Sciwind Biosciences and Gan & Lee Pharmaceuticals for obesity and type 2 diabetes, administered as a once-weekly subcutaneous injection.